Decipher by Veracyte

Veracyte offers Decipher genomic tests for urologic cancers.

[Decipher by Veracyte @Decipher_VCYT]

We're excited to be at the PTCOG-NA 12th Annual Meeting in Washington, DC, Nov. 6-8. Visit the @Veracyte booth to connect with our team and learn how Decipher® Prostate and Decipher® Bladder testing can help support treatment planning in #ProstateCancer & #BladderCancer

[Decipher by Veracyte @Decipher_VCYT]

We’re excited to be exhibiting at LUGPA Annual Meeting 2026, in Chicago, IL, November 5-7, 2026. Visit our booth to learn how #DecipherTesting by @Veracyte can help provide additional clarity for treatment planning. #DecipherUrologicCancers #PrecisionMedicine

[Decipher by Veracyte @Decipher_VCYT]

Join us at the Urology Research and Education Symposium in River Vale, NJ, on November 5! Visit our booth to learn how #DecipherTesting by @Veracyte can provide additional clarity for #ProstateCancer and #Bladder Cancer treatment planning. #DecipherUrologicCancers

[Decipher by Veracyte @Decipher_VCYT]

We’re here at LUGPA Annual Meeting 2026, in Chicago, IL, November 5-7, 2026! Visit the #TeamVeracyte booth to learn how Decipher® Prostate and Decipher® Bladder testing help support a personalized approach to care for those with prostate & bladder cancer. @Veracyte, Inc.

[Decipher by Veracyte @Decipher_VCYT]

We’re at the Chicago Urological Society (CUS) Prostate Meeting 2026 November 4 in Chicago, IL! Visit #TeamVeracyte to learn about Decipher® Prostate test and how they can help inform treatment planning. #DecipherUrologicCancers #PrecisionMedicine @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

Our team is at the 2026 Alabama Urology Network (AUN) in Point Clear, AL, Oct 30-November 1! Visit the Team @Veracyte, Inc. booth today or tomorrow to learn how Decipher® Prostate & Decipher® Bladder tests support a more personalized approach to care in prostate & bladder cancer.

[Decipher by Veracyte @Decipher_VCYT]

We’re excited to be at Western Section American Urological Association SurgeWest 2026 (WSAUA) in Lahaina, HI, Oct 25–30! Stop by & meet #TeamVeracyte to learn how Decipher® Prostate & Decipher® Bladder tests can help inform treatment planning in #ProstateCancer & #BladderCancer

[Decipher by Veracyte @Decipher_VCYT]

Join us at #WSAUA SurgeWest 2026 in Lahaina, HI (Oct. 25-30)! Stop by the @Veracyte booth to learn how #DecipherProstate and #DecipherBladder testing help inform treatment planning. #DecipherTesting #PrecisionMedicine

[Decipher by Veracyte @Decipher_VCYT]

We’re excited to be at 95th Annual Meeting of the New England section of the AUA, in Hartford, CT, Oct 22–24! Stop by & meet #TeamVeracyte to learn how Decipher® Prostate & Decipher® Bladder tests can help inform treatment planning in #ProstateCancer & #BladderCancer @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

Join #TeamVeracyte at the NCUA 11th Annual Meeting, Oct. 23-24 in Wilmington, NC! Learn how Decipher® Prostate and Decipher® Bladder provide genomic insights to support treatment planning in #ProstateCancer and #BladderCancer. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

We’re at 95th Annual Meeting of The New England AUA, October 22-24 in Hartford, CT! Visit our booth to learn how #DecipherTesting by @Veracyte can support more informed treatment decisions for patients with #ProstateCancer. #PrecisionMedicine #DecipherUrologicCancers

[Decipher by Veracyte @Decipher_VCYT]

#TeamVeracyte is at the Kentucky Urological Association (KUA) 2026 Annual Meeting, in Lexington, KY, October 17! Stop by to learn how #DecipherTesting can help provide actionable insights for treatment planning for those with #ProstateCancer & #BladderCancer. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

We’re here at 100th Annual Meeting of the North Central Section of the AUA, Oct 14-17, 2026! Visit the #TeamVeracyte booth to learn how Decipher® Prostate & Decipher® Bladder testing help support a personalized approach to care for those with prostate & bladder cancer. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

Join #TeamVeracyte, at the 1st Annual Jefferson Urology Symposium in King of Prussia, PA! Stop by our booth to learn how Decipher® Prostate & Decipher® Bladder testing provide genomic insights to support care decisions in #ProstateCancer & #BladderCancer. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

We're heading to the MedStar Health Advances in Urologic Oncology 2026! Visit the #TeamVeracyte booth in Washington, DC, to learn how Decipher® Prostate & Decipher® Bladder testing can help support clinical decision-making across #ProstateCancer & #BladderCancer care. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

We’re here at 100th Annual Meeting of the North Central Section of the AUA, October 14-17, 2026! Visit #TeamVeracyte booth to learn how Decipher® Prostate &Decipher® Bladder testing help support a personalized approach to care for those with prostate and bladdercancer. @Veracyte

[Decipher by Veracyte @Decipher_VCYT]

Attending the OhioHealth Fall Cancer Conference 2026? We'd love to connect! Stop by the #DecipherTesting by @Veracyte booth October 9-10 in Powell, OH, to meet our team and learn how we can help support more personalized care for patients with #ProstateCancer & #BladderCancer.

[Decipher by Veracyte @Decipher_VCYT]

We’re at the Connecticut Urology Society Annual Education Meeting! Stop by our booth on October 8 in Southington, CT, to learn how #DecipherTesting by @Veracyte can help provide additional information to support treatment planning in #ProstateCancer & #BladderCancer patients.

[Decipher by Veracyte @Decipher_VCYT]

We're excited to be at the 2026 Advances in Prostate Cancer Management, October 8-9. Visit our booth to connect with our team & learn how Decipher® Prostate & Decipher® Bladder testing can help support treatment planning in #ProstateCancer & #BladderCancer. @Veracyte

[Veracyte, Inc. @Veracyte]

We are proud to announce new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.

The results, which will be presented at the #ASTRO26 Annual Meeting (Abstract #312), demonstrate that the Decipher® Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term androgen deprivation therapy (ADT) to dose-escalated radiation, providing Level 1B* prognostic and predictive evidence.

| Impact |

The findings provide the first evidence that Decipher testing can predict hormone therapy benefit in intermediate-risk prostate cancer, extending its long-established role in assessing the risk of prostate cancer progression to informing treatment selection for patients with intermediate-risk disease.

While ADT can reduce the risk of recurrence and distant spread, it can also have metabolic and quality-of-life effects. Because intermediate-risk disease is biologically diverse, clinical variables such as Gleason grade, prostate-specific antigen (PSA) or clinical stage alone may not reveal which patients are most likely to benefit from adding the therapy.

The NRG/RTOG 0815 trial analysis helps move #DecipherProstate testing closer to answering  a consequential question in prostate cancer care: Will hormonal therapy make a meaningful difference for this patient? Study author, Angela Jia, M.D., Ph.D. will present the results.

| Presentation Details |

📅 Date: Tuesday, September 29

⏰ Time: 3:55pm – 4:05pm ET

📍 Location: Room 210

*Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101, 1446–1452 (2009). https://t.co/lYxj7nr44Q

| Resources|

📄 Read full press release - https://t.co/SlRRy8XmsD

🔗 Event information - https://t.co/JzjLjE5MKN

#RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte

This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: https://t.co/fQcKkGFugi